Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection | MicrobiomeTrials← Back to trialsNCT05330455
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
TERMINATEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-04-14Est. Completion: 2025-05-19
Enrollment target: 74 participants Locations- GSK Investigational Site, Calgary, Alberta, Canada
- GSK Investigational Site, Ottawa, Ontario, Canada
- GSK Investigational Site, Grenoble, France
- GSK Investigational Site, Nantes, France
- GSK Investigational Site, Rennes, France
- GSK Investigational Site, Milan, Italy
- GSK Investigational Site, Monza MB, Italy
- GSK Investigational Site, Daegu, South Korea
- GSK Investigational Site, Pusan, South Korea
- GSK Investigational Site, Seoul, South Korea
- GSK Investigational Site, Bangkok, Thailand
- GSK Investigational Site, Cambridge, United Kingdom
- GSK Investigational Site, London, United Kingdom
- GSK Investigational Site, London, United Kingdom
Other microbiome trials you might be interested in
Chronic Hepatitis B e Antigen PositiveChronic Hepatitis B e Antigen Negative
Background:
\- Chronic infection with the hepatitis B virus may lead to cirrhosis, liver disease, and cancer of the liv…
Bethesda, United States
Hepatitis CHepatitis B
This study will evaluate hepatitis C virus (HCV) infection in blood donors who test positive for antibodies to this viru…
Bethesda, United States
An appropriate hypothalamic-pituitary-adrenal (HPA) axis response is required to survive critical illness. Primary adren…